In Hawaii for a few more weeks promised the girlfriend that I won’t be posting much at all until I get back. Hepa should start moving soon. Hope all is well!

$Hepa

Charts doing its thing I added under $2.00 a big bag will keep adding . Believe it or not charts looks great.
Happy. 4th everybody I’m logging off for the holiday weekend see you Tuesday am with a nice PR perhaps!

$Hepa

What a beast this spaceship is revving up.

Stair stepping to new highs soon.


And ready to launch Sir Richard into outer space.

Hello Bears!
https://tenor.com/view/wavingbear-hi-hello-gif-19777140

$SPCE

$2.15 last trade after hours.

"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH

NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.

In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.


HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.

Pole dancing and scarfing down chili dogs that roach!

Now back to business!

Just getting in my steam and sauna.

This is going to he a legendary run one for the record books!


$HEPA

So sausage makers closed out positions at the end of the quarter little reshuffling here and there.

New quarter lots of catalysts lined up there is just a sliver of retail shares available. If you been watching this trade they have been trying very hard to scare retail and add to the golden stash. Know what you own. Don’t get robbed for your shares. PDSB was down at these levels 2.00 range near 30% down year to date and then out of now where the stock surged almost 600% don’t be a pole smoker and get robbed for your shares!! You will never recover from owning a stock that’ jumps 500% to a 1000% after you sold for a loss of got your stopped taken out. If you can’t handle a little volatility don’t look at the stock for a few months and you will be see a big lift off from these levels. My money is here and I will keep adding at these levels. No brainer! Remember ARKO and MDGL have inferior Nash drugs and have 1.6 and 1.1 billion market caps HEPA 150 million market cap 115 million in cash with their drug at CRV431 at 75mg is showing efficacy at 28 days what’s MDGL has taken 3 months put your big boy pants and enjoy the ride! FDA already gave the go ahead for 2B in the coming months the higher mgs data is coming the sophisticated AI powr platform is key here.

These crooked MM have been loading huge on the bid and selling small lots all week wake up to scare retail.

This stock is going to go parabolic with or without you. Book it!

$HEPA

Be patient! Be patient!

That’s a big mental game boys, they create fear and doubt to scare us with the stock price. Nothing change in fact.

Keep your shares strong.
I had enough experience to told you many good news will come in the next weeks.

Let’s give a chance to Dr Foster to show us whats behind thousands and thousands hours of sacrefice/efforts In the lab.

Catalyst / News coming:

Phase 2A / 225 mg dose
Phase 2B starts 2021

Dr Hobbs join Hepion in Feb Vice President snd CMO of Novo Nordisk 190 billion dollar company.

Hobbs leaves a 183 Billion dollar company with the one the biggest pharmaceutical companies with a very cushy job and you can damn well bet that he didn't leave his VP/CMO position thto take lead CMO at HEPA think about it! He's not going to Hepa to play %$%& tiddlywinks
http://www.pharmafile.com/news/521552/working-life-dr-todd-hobbs-vice-president-and-chief-medical-officer-novo-nordisk

Dr Mayo SVP

AI POWR platform +

115 million in cash burning under 5 million a quarter.

150 million market cap.


85%~90% of shares being held by institutions and insiders after the 2 offerings strong cash position!

- Partnership / Mix CRV-431 with others pills / molecule
- News Positive effects of CRV-431
Hepa other possible indications:
Diabetes.
Hepatitis
HVB.
Alzheimer’s
NASH Nash drug CRV431( 500 Million patients in the world )
Covid.
Endometrial Carcinoma.

100x ROI potential from these levels by 2025


Hepa competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions

In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.


The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach $84 Billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029


Lastly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then. Also the chart just reversed.

There are no shares available the MM are swapping spit with one another's accounts trying to pry loose a few shares from weak pathetic and uneducated retail types. HEPA stock can double or triple in a blink of an eye just have the vision and patience and balls of fortitude. Diamond hands laser eyed Hepa Bulls long & strong! This small biotech 160 million market cap has potential to reach tens of billions of dollars buy hold and forget about it and lock up your shares up.


Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 150 Million market cap 120 million in cash

$HEPA

Todd Hobbs new CMO Hepa pharmaceuticals.
https://www.amga.org/about-amga/subsidiaries/foundation/amga-foundation-board/todd-hobbs/

How does a piss money Java call center troll have a half of follower between 2 stock boards you can’t make this stuff up.

$HEPA

My associate who sold a biotech company to Becton Dickinson and now heads a top 100 crypto project did me a favor and Dialed the IR today he owns a boatload of Hepa shares.

His takeaways from his conversation with IR

Clinical portion of dosing/treatment has been completed!

Data collection has been compiled and top line results will be released sooner than later these things take time to put together!

Should be in the coming days. No official time set, but releasing in the near future!

Top line results will be released and then further data analysis will take place after the release 75mg data was great, 150mg & 225mg data will determine optimal dosage moving forward All about determining patient safety on dosing!

Besides that if you do your homework with laser like focus you know there is a myriad of catalyst about to drop!

HEPA similar pattern to ATOS 3 months ago chart before the price surge!!

$Hepa

Blue sky breakout!


$BEAM

RSI way OVERSOLD!

Legendary move in motion.

Block the circus clowns working overtime at the 3rd world call centers especially the clown with a half of follower on IHUB & ST biggest loser of all time!

$HEPA

Nice!!


Starting to Think there is a buyout happening this makes a lot of sense to me excogitating on this over the weekend some more. Big buys on Friday 212k and other large orders. I’m going to be loading Monday morning if the price is under 2.30-2.40 I’m guessing the suitor is Gilead. or Novo Nordisk.

A 160 Million market cap for HEPA in this market is very small. Also my friend again pounded the table to me on the similarities on the ATOS chart and the HEPA chart he is adamant that the Hepa chart is almost identical in pattern formations to where ATOS was 3 months ago. This would take us to the first target on the charts into low mid $8.00 range. Hold strong filter out the noise snd let’s hit another home run together ladies and gentlemen.

Also very few shares floating and the company has over 115 million in cash and has a extremely low burn rate of 4.75 million a quarter under 5 million is a LOW BURN RATE! Small team of highly skilled professionals who have more experience in the Cyclophilin inhibitors area than anyone else on the planet




HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action

Blocked!!

$HEPA!

I don't think so someone wants shares & working over time to get cheapies from inexperienced impatient folks.


Trading under cash value. I'm telling you this is going to launch into outer space soon.


Made 3 buys today took some profits from my other positions to add overweight here!


Red to green & the mother of all reversals coming for a supersonic move! Book it.


$HEPA

Red to green type move.

New quarter watch out shorts!


$SPCE

Anyone else left to be shaken out before it reverses?

Call the police if you sold your shares you have been robbed the police won't come & save you they have been defunded!!

Cup and handle clowns & pole pie stuffers choke & gag on the sausages!

HEPA is trading below its cash value absolutely MM sausage gaging pole tactics. Lets steamroll these toothless fruity buffoons over.

$HEPA

where is the cream puff marshmallow lady gaging on sausages!
https://giphy.com/gifs/clown-slapstick-pie-in-the-face-KfI6Y0KhP2Rg6A3tzh

KABOOM


$PDSB

Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee


How about them apples!


$BEAM

Beam me up Scotty lol lmao

Beasting out!

$BEAM

Coiled spring wanting to breakout!! Amateurs have sold to strong hands!!

$HEPA

Laser eyes diamond hands no one said this was going to be easy.

Paper hands will chase buy higher and own less shares.

These monkeys are trying to hard to steal our shares not happening.

We have a biotech company trading near cash levels with an all star team and a wide array of blockbuster potential.

Has the potential to skyrocket at a moments notice!! Multiple catalysts and hammers ready to drop!

Todd Hobbs key high level executive for 17 years at novo nordisk a 190 billion dollar company is the new chief medical officer of HEPA!

$HEPA

Hepa Love this chart..... all indicators are curling up!

MM is trying too hard to steal shares from impatient retail they want these shares so so bad it's captain obvious!


Added + shares dip buy opportunity IMHO expecting a big breakout soon.


Multiple catalyst & hammers the company has in its back pocket there are very few retail shares floating.


The perfect ingredients for a big breakout.

HEPA CRV431 is a blockbuster drug for a myriad of indications.

Published today
Cyclophilin B
promotes cell proliferation and metastasis in endometrial carcinoma
Conclusion
The results of our study suggest that CypB may serve as a novel regulator of endometrial cell proliferation and metastasis, thus representing a novel target for gene-targeted endometrial therapy.
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08374-7

HEPA June 2021 Biz Presentation:
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf


$HEPA

https://finance.yahoo.com/quote/HEPA?p=HEPA&.tsrc=fin-srch


Bullish pattern detected = Momentum!

Short term outlook: Bullish (2 week to 6 weeks)

Medium term outlook: Bullish (6 weeks to 9 months)

Long Term outlook: Bullish (9-months+)


$HEPA

Bitcoin s a swarm of cyber hornets serving the goddess of wisdom, feeding on the fire of truth, exponentially growing ever smarter, faster, and stronger behind a wall of encrypted energy.

Michael Saylor

$MSTR

Yes I added a few shares to the stash this am.I have dozens of people in my circles invested heavy on HEPA. Multiple scooped up more shares on the dip this morning.

Smart money buying MM trying to squeeze retail won't work the shares are locked up in strong hands.
Hepa can launch into outer space on a dime. Add the dips before she rips.

MM about to choke & gag on their sausages!
https://giphy.com/gifs/dump-part-13AurJL9v5Oo48




$HEPA

Red to green Shorties about to get REKT.


$SPCE

Very weak attempt to keep the stock price down this is about to surge hard!

I see the angles before they are being played!

Parabolic move in the making book it!


$Hepa

$4.00's on deck.

New highs in the forecasts.

$MNMD

Stair stepping into blue skies territory!


$SPCE

Kaboomage


$BEAM

Hepa will go huge soon!


Primed to run!


Adding this morning thank you for the opportunity to add to my stash.


Small Biotech with unlimited upside.


HRPA CRV431 molecule in action

Cantor Fitzgerald Initiates Coverage On PDS Biotechnology with Overweight Rating, Announces Price Target of $25


PDSB

Major & Emerging Players in Liver Cirrhosis Market:-

F.Hoffmann-La Roche AG (Switzerland),Merck & Co., Inc (United States),Abbott Laboratories (United States),Novartis International AG (Switzerland),Bristol Myers Squibb Company (United States),Gilead Sciences, Inc (United States),Conatus Pharmaceuticals (United States),GlaxoSmithKline plc (United Kingdom),Grifols, S.A. (Spain),GWOXI Stem Cell Applied Technology Co., Ltd (China),Hepion Pharmaceuticals (United States),Intercept Pharmaceuticals, Inc. (United States),Lepu Medical Technology (Beijing) Co., Ltd. (China)
https://erxnews.com/news/336525/liver-cirrhosis-market-analysis-major-competitor-and-strategies-regional-outlook-2021-to-2026/

Hepa textbook cup & handle pattern is formed.



Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash burning under 5 million a quarter



$HEPA

Hepion is on this short list, among giants. Hint Hint.
Liver Cirrhosis Market Analysis Major Competitor And Strategies Regional Outlook 2021 To 2026
https://erxnews.com/news/336525/liver-cirrhosis-market-analysis-major-competitor-and-strategies-regional-outlook-2021-to-2026/

They can tout Madrigal's P3 lead NASH drug all they want, but the fact of the matter is that it didn't move their stock up, and it actually ended down a bit, very close to the 52-week low.
That sure as hell doesn't sound like any sort of a blockbuster.
The big operators all have top researchers, and you can see they were about as far from jumping through flaming hoops as one could be, when this data was presented at EASL.
Either something ain't quite right with their drug, or there's something the big boys know about that's coming from elsewhere that blows away the Madrigal numbers.

Let's not forget that the low dose (75mg) of CRV431 did in just 28 days what Madrigal's drug took 12 weeks to accomplish.
What's the 225mg dose of CRV431 gonna do, and what about over more time than that ultra-brief 28 day period? Blow Madrigal completely out of the water, or what?




Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash burning under 5 million a quarter

$HEPA

They can tout Madrigal's P3 lead NASH drug all they want, but the fact of the matter is that it didn't move their stock up, and it actually ended down a bit, very close to the 52-week low.
That sure as hell doesn't sound like any sort of a blockbuster.
The big operators all have top researchers, and you can see they were about as far from jumping through flaming hoops as one could be, when this data was presented at EASL.
Either something ain't quite right with their drug, or there's something the big boys know about that's coming from elsewhere that blows away the Madrigal numbers.

Let's not forget that the low dose (75mg) of CRV431 did in just 28 days what Madrigal's drug took 12 weeks to accomplish.
What's the 225mg dose of CRV431 gonna do, and what about over more time than that ultra-brief 28 day period? Blow Madrigal completely out of the f'n water, or what?

Hepion is on this short list, among giants. Go figure!
Liver Cirrhosis Market Analysis Major Competitor And Strategies Regional Outlook 2021 To 2026
https://erxnews.com/news/336525/liver-cirrhosis-market-analysis-major-competitor-and-strategies-regional-outlook-2021-to-2026/



Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash burning under 5 million a quarter

$HEPA

Love the volume on Friday. And the upward continuation calm before the storm. Chart looks golden.

$MNMD

Update on Brazil this week that trials have commenced would be money ball.

$PDSB

Opens over 60.00 tomorrow morning!

$SPCE

Starting to Think there is a buyout happening this makes a lot of sense to me excogitating on this over the weekend some more. Big buys on Friday 212k and other large orders. I’m going to be loading Monday morning if the price is under 2.30-2.40 I’m guessing the suitor is Gilead. or Novo Nordisk.
A 167 Million market cap for HEPA in this market is very small. Also my friend again pounded the table to me on the similarities on the ATOS chart and the HEPA chart he is adamant that the Hepa chart is almost identical in pattern formations to where ATOS was 3 months ago. This would take us to the first target on the charts into low mid $8.00 range. Hold strong filter out the noise snd let’s hit another home run together ladies and gentlemen.
Also very few shares floating and the company has over 115 million in cash and has a extremely low burn rate of 4.75 million a quarter under 5 million is a LOW BURN RATE! Small team of highly skilled professionals who have more experience in the Cyclophilin inhibitors area than anyone else on the planet

$HEPA

Hepa targets are the $8:25-$8:50 range and then $16.00-$17.00 range I will sell incrementally at those 2 target area’s and then ride the rest free shares. I really believe this company can fetch a 50-100 billion market cap within 5 years. Nash competitors AKRO & MDGL have a 1.2 billion and 1.7 billion market cap with safety records no where near as safe as HEPA molecule CRV431 and the top line doses on low mg 75mg are inline with MDGL phase 3 Hepas larger milligrams 150 and 225mg should blow MDGL out of the water. Remember Foster the CEO said CRV431 was so safe that you could put it in the drinking water. On a disease like NASH with no FDA approved drugs. The FDA really would first and foremost will be looking for a drug that is safe. CRV431 is that drug that has the potential to treat a wide array of indications along with NASH including other cancers, diabetes, Alzheimer’s. The imperative take away is Hobbs leaving a high level executive position for 17 years at Novo nordisk a 190 billion dollar company. He ain’t coming to be the CMO.Chief medical officer to a micro cap biotech company like HEPA unless there was proof of that the molecules results are PROFOUND.
ATOS 3 month chart looks similar to where HEPA is today. ATOS moved from 1.45 to high 9.00s in a hundred days. Be patient accumulate Hepa at these levels! IMO.

$HEPA